IP Library Granted Patent US 7,329,743
Granted Patent B2
US 7,329,743 · App. 10/830,702 · Granted Feb 12, 2008

Gene encoding labyrinthin, a marker for cancer

Assignee: ImmvaRx, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,329,743
App. No.
10/830,702
Granted
Feb 12, 2008
Kind
B2
Abstract

A cDNA molecule that encodes a protein designated Labyrinthin (Lab) is isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells.

Claims (4)

1. An isolated cDNA molecule with a nucleotide sequence selected from the group of nucleotide sequences consisting of SEQ ID NO: 1, and a segment of the isolated cDNA molecule having SEQ ID NO: 1 wherein the segment extends from the start codon (ATG) to the stop codon TAA in the nucleotide sequence and includes 765 base pairs.

2. A vector comprising an isolated cDNA molecule of claim 1 .

3. A vector comprising an isolated cDNA molecule encoding SEQ ID NO: 2.

4. A cDNA molecule that encodes a peptide consisting of the amino acid sequence selected from the group consisting of APPEDNPVED (SEQ ID NO: 6), EEQQEVPPDT (SEQ ID NO: 7), DGPTGEPQQE (SEQ ID NO: 8), EQENPDSSEPV (SEQ ID NO: 9) and PTGEPQ (SEQ ID NO: 10).

Assignments (2)
MERGER Recorded Jan 16, 2018
From: IMMVARX, INC.
To: MISSION THERAPEUTICS, INC.
Reel/Frame 044632/0113 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2018
From: MISSION THERAPEUTICS, INC.
To: OPUS CRYSTAL HOLDINGS LIMITED
Reel/Frame 044632/0246 →
Continuity (4)
Division 0965952100 · Sep 12, 2000
Continuation PCTUS990536500 · Mar 11, 1999
Continuation In Part 0904048500 · Mar 17, 1998
Related Publication 20050208508A1 · Sep 22, 2005